The Supreme Court has criticized large price gaps in cancer medicines, highlighting potential violations of the 2013 Drug Price Control Order. The court’s scrutiny of hospital-linked pharmacies could signal regulatory pressure on the pharmacy margins of private hospital chains, which often form a significant part of their revenue.
The Supreme Court of India has raised concerns over the pricing of essential cancer medications, calling the gap between manufacturer supply costs and final consumer prices a form of financial hardship for patients. During a hearing on September 29, 2026, a Bench consisting of Justices Vikram Nath and Sandeep Mehta questioned why the 16% retail margin limit, established under the Drugs (Prices Control) Order (DPCO) of 2013, is not strictly followed.
The Court noted that in several instances, essential cancer drugs are being sold to patients at prices significantly higher than the rates supplied to retailers. The judiciary pointed out a systemic practice within private hospitals where patients are often required to purchase medicines from in-house hospital pharmacies. This setup effectively removes the patient's ability to compare prices or shop for lower-cost alternatives, creating a captive market.
From a financial and business perspective, this development is significant for the private hospital sector. Many large hospital chains in India rely on their pharmacy and diagnostic arms as high-margin revenue contributors. If regulators enforce stricter transparency or cap margins on these pharmacy sales, it could potentially impact the operating margins of hospital operators. The government noted that these inflated costs also place a burden on public healthcare schemes, such as Ayushman Bharat, by increasing the total reimbursement costs for treatment.
Legal proceedings were initiated by advocate Kishan Chand Jain and surgeon Sanjay Kulshrestha, aiming for better price controls on medical equipment and generic drugs. The Bench highlighted that many families face severe financial distress, often having to sell assets to afford life-saving treatment, leading the Court to describe the current pricing disparities as a major concern for public welfare.
The government has requested additional time to provide details on the current regulatory framework. The Supreme Court has scheduled the next hearing for October 12, 2026. Investors and market watchers are expected to monitor whether the Court’s observations lead to specific mandates regarding hospital pharmacy operations, mandatory generic prescriptions, or broader revisions to the DPCO framework to ensure more uniform pricing across the medical retail supply chain.